Back to results
US 12,600,732 B2Granted
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
AssigneeNurix Therapeutics, Inc.
InventorsAileen Kelly, Arthur T. Sands
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Claims36
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
Dependencies are inferred from the claim text.